<?xml version="1.0" ?>
<document id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444">
  <chunk id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c0" text="The Prevalence and Significance of HTLV-I/II Seroindeterminate Western Blot Patterns"/>
  <chunk id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1" text="Human T-lymphotropic virus type I (HTLV-I) infects an estimated 15-20 million persons worldwide. A number of diseases have been associated with the virus including adult T-cell leukemia (ATL), HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-I uveitis, and HTLV-I-associated infective dermatitis. Once it was shown that there is an increased risk for developing HAM/TSP associated with blood transfusion, screening for HTLV-1 among blood banks was implemented in Japan, United States, France, and the Netherlands. This process includes detection by an enzyme immunoassay (EIA) followed by a confirmatory Western blot (WB) in which recombinant proteins specific for HTLV-I Env glycoproteins are incorporated into WB strips. HTLV-I seropositive results are defined by the presence of antibodies against either gp46 or gp62/68 (both Env protein bands) and either p19, p24, or p53 (one of the gag bands). HTLV-II seropositivity is confirmed by the presence of rgp46-II. However, numerous cases have been documented in which serum samples are reactive by EIA, but an incomplete banding pattern is displayed by subsequent confirmatory WB. Although the significance of these HTLV-I/II seroindeterminates is unclear, it may suggest a much higher incidence of exposure to HTLV-I/II than previously estimated.">
    <entity charOffset="666-674" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e0" ontology_id="CHEBI_36080" text="proteins" type="chemical"/>
    <entity charOffset="699-712" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e1" ontology_id="CHEBI_17089" text="glycoproteins" type="chemical"/>
    <entity charOffset="857-864" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e2" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="912-915" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e3" ontology_id="CHEBI_143889" text="gag" type="chemical"/>
    <pair e1="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e0" e2="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e1" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.p0" relation="true"/>
    <pair e1="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e0" e2="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e2" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.p1" relation="true"/>
    <pair e1="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e0" e2="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e3" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.p2" relation="true"/>
    <pair e1="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e1" e2="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e2" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.p3" relation="true"/>
    <pair e1="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e1" e2="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e3" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.p4" relation="true"/>
    <pair e1="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e2" e2="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.e3" id="29cc49c0a88d00ecc54d45ff5bf9128e47e9a444.c1.p5" relation="true"/>
  </chunk>
</document>
